Marina Anatolevna Teplova
◽
Irina Nikolaevna Krugova
◽
Yuliia Anatolevna Moiseyenko
◽
Natalia Nikolaevna Shchyt
In order to study the molecular biological markers of the tumor in patients with endometrial cancer stages I−IV, the patients who received a combined treatment at the Department of Oncological Gynecology at the State Institution "Grigoriev Institute for Medical Radiology" were surveyed. The study has demonstrated that in the patients with advanced endometrial cancer, the expression rate of molecular biological markers and ER and PR receptors depends on the histological shape of the tumor. In adenocarcinomas with a high degree of differentiation, the value of both positive and negative VEGF was observed in equal percentages, against the background of high Bcl−2 expression, negative mt p53 expression, and negative or moderate proliferative activity. In patients with adenocarcinoma with moderate degree of differentiation, the value of positive VEGF was observed three times more often than negative one, against the background of a high Bcl−2 expression, negative mt p53 expression and moderate proliferative activity (Ki67). In the patients with low−grade adenocarcinoma endometrium, both positive and negative VEGF were equal in percentage, against the background of high Bcl−2 expression, negative mt p53 expression, and positive proliferative activity. In adenocarcinomas with high and moderate degree of differentiation, the positive status of ER and PR is more often observed, and, conversely, in the patients with low−differentiated adenocarcinoma their negative status was found. It has been revealed that the level of expression of the investigated molecular biological markers and ER and PR receptors in tumors of the patients with endometrial cancer differed depending on the occurrence of relapse. This fact can be used to determine the risk of endometrial cancer recurrence.
Key words: endometrial cancer, molecular biological markers, relapse, expression.
Prognostic and predictive molecular biological markers in prostate cancer – significance of expression of genes PCA3 and TMPRSS2
